← Eichor
Condition: Renal Al Amyloidosis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Renal Al Amyloidosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Phase 2 · 3 location(s) · Peking University People's Hospital · NCT06418477DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
Phase 2 · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT06420167National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.